Trial Profile
A study of ParvOryx in combination with Avastin(R) or with Avastin(R) plus an immune checkpoint inhibitor in a controlled clinical trial setting
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2017
Price :
$35
*
At a glance
- Drugs H 1PV (Primary) ; Bevacizumab
- Indications Glioblastoma; Pancreatic cancer
- Focus Therapeutic Use
- 31 May 2017 New trial record
- 23 May 2017 According to an Oryx GmbH & Co media release, data from compassionate use programs is used to plan this trial. This trial will be discussed with regulatory authorities.